This article was originally published in The Gray Sheet
Executive SummarySummary of safety and effectiveness data on the Wallstent tracheobronchial prosthesis, which gained 510(k) clearance for device modifications on June 2, is available from FDA. The agency's list of 510(k)s cleared under summary/statement requirements in June incorrectly indicated that the information would be made available by Schneider ("The Gray Sheet" July 18, p. 13)
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.